The current work aimed at preparing a cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine] from previously established synthetic routs. The derivative was investigated for its potential anticancer activities as well as its possible mechanism of action. The prepared compound showed variable anticancer activities against all tested cell lines. Furthermore, it showed very promising activities in terms of obtained IC50 values compared to known used drugs. The mechanism of action studies showed that the prepared tripeptide may act on cancerous cells through its inhibitory action on tyrosine kinase pathway. Animal model experiments proved the potential of the synthesized tripeptide as an anticancer agent against PC3 cancer cells
The molecular basis of tumour angiogenesis has been extensively studied and the Vascular Endothelial...
Although peptides and proteins are considered as lead compounds for the discovery and development of...
A nicotinamide-based derivative was designed as an antiproliferative VEGFR-2 inhibitor with the key ...
413-417The current work aimed at preparing a cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine] from...
The current work aimed at preparing a cyclo (N-a-dinicotinoyl)-bis-[(L-valinyl)-L-lysine] from previ...
Cancer is a major risk disease affecting human survival. The pharmaceutical companies are continuing...
333–336Research is continuing for synthesizing new molecules with potent pharmacological effects aga...
During the current work, we synthesized a new peptide derivative; 4,13-diisopropyl-2,5,12,15-tetraox...
Current research aimed at evaluating the in vitro as well as in vivo anticancer activities of a newl...
Some of cyclo (Nα-di-nicotinoyl)[L-phenylalanyl-L-leucine]pentapeptides3-6 has been synthesized star...
A number of cyclo-β-tripeptides and their linear precursors were subjected to primary biol. evaluati...
VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in va...
Several tricyclic compounds inspired by the structure of combretastatin A-4 and bearing group 14 ele...
A new series of pyrazole derivatives were designed by docking into vascular endothelial growth facto...
Protein kinases dysregulation is extremely common in cancer cells, and the development of new agents...
The molecular basis of tumour angiogenesis has been extensively studied and the Vascular Endothelial...
Although peptides and proteins are considered as lead compounds for the discovery and development of...
A nicotinamide-based derivative was designed as an antiproliferative VEGFR-2 inhibitor with the key ...
413-417The current work aimed at preparing a cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine] from...
The current work aimed at preparing a cyclo (N-a-dinicotinoyl)-bis-[(L-valinyl)-L-lysine] from previ...
Cancer is a major risk disease affecting human survival. The pharmaceutical companies are continuing...
333–336Research is continuing for synthesizing new molecules with potent pharmacological effects aga...
During the current work, we synthesized a new peptide derivative; 4,13-diisopropyl-2,5,12,15-tetraox...
Current research aimed at evaluating the in vitro as well as in vivo anticancer activities of a newl...
Some of cyclo (Nα-di-nicotinoyl)[L-phenylalanyl-L-leucine]pentapeptides3-6 has been synthesized star...
A number of cyclo-β-tripeptides and their linear precursors were subjected to primary biol. evaluati...
VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in va...
Several tricyclic compounds inspired by the structure of combretastatin A-4 and bearing group 14 ele...
A new series of pyrazole derivatives were designed by docking into vascular endothelial growth facto...
Protein kinases dysregulation is extremely common in cancer cells, and the development of new agents...
The molecular basis of tumour angiogenesis has been extensively studied and the Vascular Endothelial...
Although peptides and proteins are considered as lead compounds for the discovery and development of...
A nicotinamide-based derivative was designed as an antiproliferative VEGFR-2 inhibitor with the key ...